BG
GNCA

BlackRock Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

BlackRock Group’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-613
Closed -$58K – 2977
2015
Q1 		$58K Buy
+613
New +$43.3K ﹤0.01% 2751

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Group's GNCA Position: Q2 2015 in Review

BlackRock Group sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2015, closing a stake of 613 shares — an estimated $58K sold.

BlackRock Group first reported a position in GNCA in Q1 2015 and held it in 1 quarter. The position peaked at $58K in Q1 2015. 60 funds tracked by Wall St. Rank hold GNCA as of Q2 2015.

  • BlackRock Group reported no remaining Genocea Biosciences, Inc. position as of Q2 2015 after selling out during the quarter.
  • BlackRock Group sold 613 Genocea Biosciences, Inc. shares in Q2 2015, an estimated $58K.
  • BlackRock Group first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 1 quarter.
  • BlackRock Group's Genocea Biosciences, Inc. position peaked at $58K in Q1 2015.
  • 60 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2015.

Based on BlackRock Group's 13F filing for Q2 2015, filed 7 Aug 2015.